VolitionRX Limited (VNRX) News
Filter VNRX News Items
VNRX News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
VNRX News Highlights
- VNRX's 30 day story count now stands at 3.
- Over the past 19 days, the trend for VNRX's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
Latest VNRX News From Around the Web
Below are the latest news stories about VOLITIONRX LTD that investors may wish to consider to help them evaluate VNRX as an investment opportunity.
Sidoti Events, LLC's Virtual December Small-Cap ConferenceNEW YORK, NY / ACCESSWIRE / December 5, 2023 / Sidoti Events, LLC, an affiliate of Sidoti & Company, LLC, has released the presentation schedule and weblinks for its two-day December Small-Cap Conference taking place Wednesday and Thursday, December ... |
VolitionRx Secures Approximately $5.5 Million in Belgium Regional Government Financing from Wallonie EntreprendreVolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, has closed on an aggregate of Euro 5.0 million (approximately $5.5 million) in financing from Wallonie Entreprendre S.A. ("WE") in Belgium. |
VolitionRx Limited (AMEX:VNRX) Q3 2023 Earnings Call TranscriptVolitionRx Limited (AMEX:VNRX) Q3 2023 Earnings Call Transcript November 15, 2023 Operator: Good morning, ladies and gentlemen. Thank you for standing by. Welcome to VolitionRx Limited Third Quarter 2023 Earnings Conference Call. During today’s presentation, all parties will be in a listen-only mode. Following the presentation, the conference call will be opened for questions. [Operator […] |
VolitionRx Limited Announces Third Quarter 2023 Financial Results and Business UpdateVolitionRx Limited (NYSE American: VNRX) ("Volition") today announced financial results and a business update for the third quarter ended September 30, 2023. Volition management will host a conference call tomorrow, November 15 at 8:30 a.m. U.S. Eastern Time to discuss these results. Conference call details can be found below. |
VolitionRx Limited Schedules Third Quarter 2023 Earnings Conference Call and Business UpdateVolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced it will host a conference call on Wednesday, November 15 at 8.30 a.m. U.S. Eastern Time to discuss its financial and operating results for the third quarter 2023, in addition to providing a business update. Details of this event can also be found below. |
Volition and VPG Launch Nu.Q® Vet Cancer Test in UK & IrelandVolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, and Veterinary Pathology Group (VPG), a leading high quality diagnostic laboratory, have joined forces to launch the Nu.Q® Vet Cancer Test to veterinary practices in the UK and Ireland. |
VNRX: Breakthrough Cancer Detection Method Disclosed at ESMO and in a Webinar - preliminary proof of concept work indicates simple blood test should be able to detect several types of cancer, potentially at Stages I & IIBy Steven Ralston, CFA NYSE:VNRX READ THE FULL VNRX RESEARCH REPORT VolitionRx (NYSE:VNRX) announced a new breakthrough cancer detection method at ESMO 2023 (European Society for Medical Oncology), which was followed up by an informative webinar with an informative slide deck . Each is accessible through one of the following links: Webinar : |
Volition Presents Breakthrough Liquid Biopsy Blood Test Method for Early-stage CancerVolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, has unveiled what it believes to be an entirely new cancer detection method at ESMO 2023¹, the annual congress of the European Society for Medical Oncology. |
Measuring Nucleosomes Using Nu.Q® NETs is a Promising Biomarker for Septic ShockVolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, announces the publication of a clinical paper1 which shows that Volition's Nu.Q® NETs test is a promising biomarker for the evaluation of disease severity in septic shock patients and could play an important role in sepsis prognosis. |
US Ambassador Adler visits Belgian VolitionVolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, welcomed Ambassador Michael M. Adler, U.S. Ambassador to the Kingdom of Belgium for a tour of its purpose-built research, development and manufacturing facilities situated in Isnes, Belgium. |